EUVIMEDEUVIMED entdecken
Crossref

Image-Based Consensus Molecular Subtyping Refines Prognostication in Stage II/III Colorectal Cancer: A Retrospective Analysis of the SCOT Trial

Maxime W Lafarge iD, Andrea Harkin iD, Tim Iveson iD, Mark Saunders, David J Adams iD, Karin Oien iD, Noori Maka iD, Kathryn Gilroy iD, Jennifer Hay iD, Bernard Hild iD, Ingrid Berg iD, Joanne Edwards und 10 weitere

Journal of Clinical Oncology · 06.11.2026

DOI: 10.1200/jco-25-02761 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Clinical Oncology, online erschienen am 06.11.2026. Verfasst von Maxime W Lafarge und 21 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biomedical Engineering, Faculty of Medicine, University of Basel, Allschwil, Switzerland. Die Arbeit nennt 26 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

Risk stratification in localized colorectal cancer (CRC) remains inadequate. Transcriptome-based classifiers such as consensus molecular subtyping (CMS) improve this, but are challenging to implement. We determined the performance of a novel image-based method for CRC CMS subtyping (imCMS) using routine pathology images from the SCOT trial and investigated association of imCMS subtypes with clinicopathologic and tumor molecular and immune factors, treatment benefit, and survival.

Methods

We applied a novel imCMS classifier to stage II/III CRCs from the SCOT trial (ISRCTN59757862) which examined 3 versus 6 months of adjuvant oxaliplatin-based chemotherapy following curative-intent surgery. We determined correlates of imCMS subgroups and investigated imCMS prognostic and predictive value for CRC recurrence-free interval, overall survival (OS), and survival after CRC recurrence (SAR) by univariable and multivariable Cox regression.

Results

A total of 2,816 cases were informative for imCMS classification, of which 664 (24%) were imCMS1 (immune), 987 (35%) imCMS2 (canonical), 433 (15%) imCMS3 (metabolic), 653 (23%) imCMS4 (mesenchymal), and 79 (3%) of mixed subtype. Analysis confirmed expected associations of imCMS1 with deficient DNA mismatch repair (dMMR) and imCMS3 with KRAS mutation and revealed substantially lower intraepithelial CD8 + and intrastromal FoxP3 + T-cell infiltrate (CD8 IE -FoxP3 IS ) in imCMS4 tumors. imCMS classification was strongly prognostic independent of clinicopathologic factors, dMMR, and CD8 IE -FoxP3 IS in multivariable analysis but did not predict differential benefit from chemotherapy duration or regimen. The combination of imCMS with CD8 IE -FoxP3 IS groups defined CRC subgroups with substantially different recurrence risk. Analysis of OS and SAR revealed notable discordance in imCMS3 and imCMS4 prognostic value before and after relapse. Conclusion imCMS classification improves CRC prognostication beyond existing tumor factors and is potentially deliverable in clinical practice. imCMS prediction of therapeutic benefit requires further study.

Autor:innen und Institutionen

  • Department of Biomedical Engineering, Faculty of Medicine, University of Basel, Allschwil, Switzerland.
  • Institute of Medical Genetics and Pathology, University Hospital Basel, Basel, Switzerland.
  • Glasgow Oncology Clinical Trials Unit, University of Glasgow, Glasgow, United Kingdom.
  • Southampton University, Southampton, United Kingdom.
  • The Christie NHS Foundation Trust, Manchester, United Kingdom.
  • Wellcome Sanger Institute, Hinxton, Cambridge, United Kingdom.

ORCID-Profile: Maxime W Lafarge, Andrea Harkin, Tim Iveson, David J Adams, Karin Oien, Noori Maka, Kathryn Gilroy, Jennifer Hay, Bernard Hild, Ingrid Berg, Owen Sansom, Caroline Kelly, Timothy S Maughan, Enric Domingo, David Church

Zitieren

APA

Lafarge, M. W., Harkin, A., Iveson, T., Saunders, M., Adams, D. J., Oien, K., Maka, N., Gilroy, K., Hay, J., Hild, B., Berg, I., Edwards, J., Sansom, O., Kelly, C., Tomlinson, I., imCMS Consortium; S:CORT Consortium; TransSCOT Consortium, Kerr, R., Maughan, T. S., Domingo, E., …, & imCMS Consortium, S:CORT Consortium, TransSCOT Consortium (2026). Image-Based Consensus Molecular Subtyping Refines Prognostication in Stage II/III Colorectal Cancer: A Retrospective Analysis of the SCOT Trial. Journal of Clinical Oncology. https://doi.org/10.1200/jco-25-02761

Vancouver

Lafarge MW, Harkin A, Iveson T, Saunders M, Adams DJ, Oien K, et al. Image-Based Consensus Molecular Subtyping Refines Prognostication in Stage II/III Colorectal Cancer: A Retrospective Analysis of the SCOT Trial. Journal of Clinical Oncology. 2026. doi:10.1200/jco-25-02761

BibTeX
@article{Lafarge2026,
  author = {Lafarge, Maxime W and Harkin, Andrea and Iveson, Tim and Saunders, Mark and Adams, David J and Oien, Karin and Maka, Noori and Gilroy, Kathryn and Hay, Jennifer and Hild, Bernard and Berg, Ingrid and Edwards, Joanne and Sansom, Owen and Kelly, Caroline and Tomlinson, Ian and imCMS Consortium; S:CORT Consortium; TransSCOT Consortium, imCMS Consortium; S:CORT Consortium; TransSCOT Consortium and Kerr, Rachel and Maughan, Timothy S and Domingo, Enric and Church, David and Koelzer, Viktor H and imCMS Consortium, S:CORT Consortium, TransSCOT Consortium, imCMS Consortium, S:CORT Consortium, TransSCOT Consortium},
  title = {Image-Based Consensus Molecular Subtyping Refines Prognostication in Stage II/III Colorectal Cancer: A Retrospective Analysis of the SCOT Trial},
  journal = {Journal of Clinical Oncology},
  year = {2026},
  doi = {10.1200/jco-25-02761}
}
Kostenlos starten →